Physician profile
Asok Dasgupta
NPI 1396855359
$2,902.06
in general payments reported to CMS, 2019-2025
29 companies · $738 in 2025
The $738 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $405 · 2021: $263 · 2022: $291 · 2023: $581 · 2024: $496 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,815.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $509.31 | 2019-2024 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $379.70 | 2020-2025 | Nucala |
| Inspire Medical Systems, INC. | $191.43 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $173.22 | 2019-2025 | |
| United Therapeutics Corporation | $173.08 | 2023-2025 | Tyvaso, Tyvaso |
| Harmony Biosciences LLC | $173.00 | 2020-2025 | Wakix |
| Genzyme Corporation | $151.62 | 2019-2023 | |
| Idorsia Pharmaceuticals US INC | $121.20 | 2024 | Quviviq |
| Pulmonx Corporation | $120.30 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.01 | 2019-2022 | |
| Mylan Specialty L.P. | $106.39 | 2022-2023 | Yupelri |
| Axsome Therapeutics, INC. | $90.90 | 2023-2025 | Sunosi |
| Arbor Pharmaceuticals, INC. | $75.20 | 2020-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $72.82 | 2024-2025 | Lumryz |
| Insmed, INC. | $60.50 | 2021-2025 | Brinsupri, Arikayce |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $58.91 | 2023 | Acthar |
| Sunovion Pharmaceuticals INC. | $57.03 | 2019-2021 | |
| Resmed Corp | $37.77 | 2019 | |
| Astellas Pharma US INC | $37.65 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $29.27 | 2023 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $27.41 | 2020-2023 | Opsumit, Uptravi |
| Grifols USA, LLC | $24.50 | 2021-2023 | Prolastin-C Liquid |
| Pfizer INC. | $22.02 | 2025 | |
| Merck Sharp & Dohme LLC | $20.47 | 2021 | |
| Paratek Pharmaceuticals, INC. | $19.59 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.82 | 2020 | |
| Electromed, INC. | $15.68 | 2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $15.13 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asok Dasgupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.